RxDoctor Payments Data

Augustus Papandrea, MD

Family Medicine · Harrisburg, PANPI 1295728285

Payments from drug & device makers

$14,484in general payments, 2019–2025

Across 881 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$1K
  • Lilly USA, LLC$876
  • Boehringer Ingelheim$857
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$14,37599%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk123$1,897
AbbVie(2 entities)104$1,709
AstraZeneca74$1,659
GSK125$1,438
Lilly USA, LLC47$876
Boehringer Ingelheim46$857
Amgen54$812
Pfizer55$715
Amarin Pharma, Inc.30$477
Johnson & Johnson19$283
E.r. Squibb & Sons, L.L.C.13$228
Novartis12$190
Astellas Pharma US Inc7$190
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$189
Exact Sciences9$185
Teva Pharmaceuticals USA, Inc.10$179
Axsome Therapeutics, Inc.8$169
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$137
Sanofi Pasteur Inc.6$136
Biohaven Pharmaceutical Holding Company Ltd.7$130
Abbott6$124
Mylan Specialty L.p.4$110
Eisai Inc.3$99
Nestle Healthcare Nutrition Inc.6$89
Otsuka America Pharmaceutical, Inc.5$87
Daiichi Sankyo Inc.6$87
Esperion Therapeutics, Inc.5$85
Dexcom, Inc.4$84
IBSA Pharma Inc.4$83
Merck6$83
Takeda Pharmaceuticals U.S.A., Inc.4$67
Biohaven Pharmaceuticals, Inc.4$67
Biogen3$64
Lundbeck LLC3$62
Sumitomo Pharma America, Inc.2$55
Kowa Pharmaceuticals America, Inc.4$55
Xeris Pharmaceuticals, Inc.3$49
Halozyme Inc2$46
Phathom Pharmaceuticals, Inc.4$44
Inspire Medical Systems, Inc.2$43
Aimmune Therapeutics, Inc.3$43
Regeneron Healthcare Solutions, Inc.2$42
Ironshore Pharmaceuticals Inc.2$40
Sanofi-aventis U.S. LLC3$38
Verona Pharma, Inc.2$37
Genentech USA, Inc.2$32
Harmony Biosciences LLC2$31
Idorsia Pharmaceuticals US Inc2$31
Radius Health, Inc.1$30
Mannkind Corporation2$28
Melinta Therapeutics, LLC2$24
Bayer1$21
Cumberland Pharmaceuticals, Inc.1$19
Neurelis, Inc.1$18
Ironwood Pharmaceuticals, Inc1$18
Amneal Pharmaceuticals LLC1$17
Avanir Pharmaceuticals, Inc.1$16
OPKO Pharmaceuticals, LLC1$14
Intra-sana Laboratories1$13
Shire North American Group Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,484 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$251,525
Medicare patients
359
Services billed
4,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$185,513
JardianceEmpagliflozin159$176,134
MounjaroTirzepatide83$96,911
OzempicSemaglutide84$88,860
TrulicityDulaglutide52$76,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$69,546
JanuviaSitagliptin Phosphate44$58,008
Soliqua 100-33Insulin Glargine/Lixisenatide27$45,062
FarxigaDapagliflozin Propanediol42$43,713
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$42,635
MyrbetriqMirabegron25$22,989
LinzessLinaclotide15$20,033
XareltoRivaroxaban12$19,042
Janumet XrSitagliptin Phos/Metformin Hcl16$18,902
Tresiba Flextouch U-100Insulin Degludec18$18,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$857$188,527180 claims
PfizerEliquis$715$185,513185 claims
Lilly USA, LLCMounjaro, Trulicity$876$173,320135 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$1,659$98,209113 claims
Novo NordiskOzempic$1,897$88,86084 claims
GSKTrelegy Ellipta, Breo Ellipta$1,438$83,110103 claims
MerckJanuvia, Janumet Xr$83$76,91060 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$38$45,06227 claims
Astellas Pharma US IncMyrbetriq$190$22,98925 claims
AbbVieLinzess$1,709$20,03315 claims
Johnson & JohnsonXarelto$283$19,04212 claims
NovartisEntresto$190$11,40221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →